Compared with other PD1/PD-L1-chemotherapy combination therapeutic regimes, including pembrolizumab, atezolizumab, and sindilimab, which were approved in China or abroad as the first line therapy for patients with metastatic non-sq NSCLC without EGFRm or ALKm, only camrelizumab-chemotherapy combination therapeutic regime showed cost-effectiveness in China according to current research. The gene discussed is CD274; the disease is non-small cell lung carcinoma.